This trial is active, not recruiting.

Condition advanced hormone sensitive prostate cancer
Treatment degarelix
Sponsor Ferring Pharmaceuticals
Start date September 2014
End date September 2017
Trial size 111 participants
Trial identifier NCT02229253, 000171


Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Treatment according to standard clinical practice.
degarelix Firmagon®

Primary Outcomes

Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice
time frame: Up to 1 year

Eligibility Criteria

Male participants of any age.

Inclusion Criteria: - Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer Exclusion Criteria: - Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded - Planned intermittent or short-term (< 12 months) degarelix treatment - Planned addition of, or switch to another form of androgen deprivation therapy during the study

Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Ferring Pharmaceuticals.